FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382807714> ?p ?o ?g. }

• W4382807714 endingPage "S133" @default.
• W4382807714 startingPage "S133" @default.
• W4382807714 abstract "As new evidence emerges, gemcitabine with nab-paclitaxel is becoming increasingly more popular as first-line chemotherapy for pancreatic cancer due to its efficacy over single agent gemcitabine and it’s favourable toxicity profile over FOLFIRINOX. A systematic review and meta-analysis carried out by Lu et Al evaluating FOLFIRINOX as a second-line chemotherapy for pancreatic cancer patients that have failed gemcitabine-based chemotherapy showed a survival benefit with FOLFIRINOX compared with other second-line regimens across all six studies. To combat the adverse events associated with FOLFIRNOX it has become commonplace to use modified dosing. In a multicenter phase II study of modified FOLFIRINOX (m-FOLFIRINOX) in metastatic and locally advanced pancreatic cancer, decreased adverse events were observed with no reduction in efficacy. As a single centre in Western Australia, we have previously reported our experience of 68 patients who were treated with second-line m-FOLFIRINOX, this is an update on the previously reported data. We conducted a retrospective analysis using an electronic database of patients with locally advanced or metastatic pancreatic cancer who received second-line m-FOLFIRINOX between December 2012 and January 2023. All patients were deemed to have an ECOG performance status of 2 or less. Overall survival (OS) was estimated via the Kaplan-Meier method. There were 128 patients identified in our analysis, with 59% of the patients having metastatic disease. The median age of patients was 65 (range, 26 – 83). Dose intensity of m-FOLFIRINOX was as follows: 65% for oxaliplatin, 68% for irinotecan, 18% for bolus 5-fluorouracil (5-FU) and 68% for infusional 5-FU. The median OS of all patients was 37.0 months (95% CI, 27.0 – 49.0). The median OS of the locally advanced and metastatic pancreatic adenocarcinoma from diagnosis was 50.0 months (95% CI, 45.0 – 71.0) and 23.0 months (95% CI, 21.0 – 37.0), respectively. As demonstrated by a retrospective analysis of 128 patients in a single centre in WA, modified FOLFIRINOX is an effective second-line therapy for the treatment of locally advanced and metastatic pancreatic cancer who have failed first-line treatment with gemcitabine and nab-paclitaxel." @default.
• W4382807714 created "2023-07-02" @default.
• W4382807714 creator A5012899043 @default.
• W4382807714 creator A5016019525 @default.
• W4382807714 creator A5016551006 @default.
• W4382807714 creator A5022112281 @default.
• W4382807714 creator A5035394592 @default.
• W4382807714 creator A5037391423 @default.
• W4382807714 creator A5052709676 @default.
• W4382807714 creator A5068002067 @default.
• W4382807714 creator A5070006103 @default.
• W4382807714 creator A5080018254 @default.
• W4382807714 creator A5086832990 @default.
• W4382807714 creator A5090294760 @default.
• W4382807714 creator A5092377052 @default.
• W4382807714 date "2023-06-01" @default.
• W4382807714 modified "2023-09-25" @default.
• W4382807714 title "P-338 Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel" @default.
• W4382807714 doi "https://doi.org/10.1016/j.annonc.2023.04.394" @default.
• W4382807714 hasPublicationYear "2023" @default.
• W4382807714 type Work @default.
• W4382807714 citedByCount "0" @default.
• W4382807714 crossrefType "journal-article" @default.
• W4382807714 hasAuthorship W4382807714A5012899043 @default.
• W4382807714 hasAuthorship W4382807714A5016019525 @default.
• W4382807714 hasAuthorship W4382807714A5016551006 @default.
• W4382807714 hasAuthorship W4382807714A5022112281 @default.
• W4382807714 hasAuthorship W4382807714A5035394592 @default.
• W4382807714 hasAuthorship W4382807714A5037391423 @default.
• W4382807714 hasAuthorship W4382807714A5052709676 @default.
• W4382807714 hasAuthorship W4382807714A5068002067 @default.
• W4382807714 hasAuthorship W4382807714A5070006103 @default.
• W4382807714 hasAuthorship W4382807714A5080018254 @default.
• W4382807714 hasAuthorship W4382807714A5086832990 @default.
• W4382807714 hasAuthorship W4382807714A5090294760 @default.
• W4382807714 hasAuthorship W4382807714A5092377052 @default.
• W4382807714 hasBestOaLocation W43828077141 @default.
• W4382807714 hasConcept C121608353 @default.
• W4382807714 hasConcept C126322002 @default.
• W4382807714 hasConcept C143998085 @default.
• W4382807714 hasConcept C197934379 @default.
• W4382807714 hasConcept C2776694085 @default.
• W4382807714 hasConcept C2777148230 @default.
• W4382807714 hasConcept C2780210213 @default.
• W4382807714 hasConcept C2780258809 @default.
• W4382807714 hasConcept C2780259306 @default.
• W4382807714 hasConcept C2780962732 @default.
• W4382807714 hasConcept C526805850 @default.
• W4382807714 hasConcept C71924100 @default.
• W4382807714 hasConceptScore W4382807714C121608353 @default.
• W4382807714 hasConceptScore W4382807714C126322002 @default.
• W4382807714 hasConceptScore W4382807714C143998085 @default.
• W4382807714 hasConceptScore W4382807714C197934379 @default.
• W4382807714 hasConceptScore W4382807714C2776694085 @default.
• W4382807714 hasConceptScore W4382807714C2777148230 @default.
• W4382807714 hasConceptScore W4382807714C2780210213 @default.
• W4382807714 hasConceptScore W4382807714C2780258809 @default.
• W4382807714 hasConceptScore W4382807714C2780259306 @default.
• W4382807714 hasConceptScore W4382807714C2780962732 @default.
• W4382807714 hasConceptScore W4382807714C526805850 @default.
• W4382807714 hasConceptScore W4382807714C71924100 @default.
• W4382807714 hasLocation W43828077141 @default.
• W4382807714 hasOpenAccess W4382807714 @default.
• W4382807714 hasPrimaryLocation W43828077141 @default.
• W4382807714 hasRelatedWork W1523425138 @default.
• W4382807714 hasRelatedWork W1988326884 @default.
• W4382807714 hasRelatedWork W2012954058 @default.
• W4382807714 hasRelatedWork W2138640290 @default.
• W4382807714 hasRelatedWork W2410090482 @default.
• W4382807714 hasRelatedWork W2599910524 @default.
• W4382807714 hasRelatedWork W2752330535 @default.
• W4382807714 hasRelatedWork W2910998150 @default.
• W4382807714 hasRelatedWork W2966671351 @default.
• W4382807714 hasRelatedWork W3045328550 @default.
• W4382807714 hasVolume "34" @default.
• W4382807714 isParatext "false" @default.
• W4382807714 isRetracted "false" @default.
• W4382807714 workType "article" @default.